IP Library › Granted Patent US 12,529,072
Granted Patent B2
US 12,529,072 · App. 18/051,659 · Granted Jan 20, 2026

Transcription modulation in animals using CRISPR/CAS systems

Inventors: Charleen Hunt (Dumont, NJ); Suzanne Hartford (Putnam Valley, NY); Guochun Gong (Pleasantville, NY); Brian Zambrowicz (Sleepy Hollow, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12N15/8509A01K67/0275C12N9/22C12N15/113C12N15/86C12N15/907A01K2217/07A01K2217/072A01K2217/206A01K2227/105A01K2267/03A01K2267/0306A01K2267/0362C12N2015/8527C12N2310/20C12N2310/531C12N2320/11C12N2750/14143C12N2800/30C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,529,072
App. No.
18/051,659
Granted
Jan 20, 2026
Kind
B2
Abstract

Non-human animal cells and non-human animals comprising CRISPR/Cas synergistic activation mediator system components and methods of making and using such non-human animal cells and non-human animals are provided. Methods are provided for using such non-human animals to increase expression of target genes in vivo and to assess CRISPR/Cas synergistic activation mediator systems for the ability to increase expression of target genes in vivo.

Claims (43)

1 . A non-human animal comprising a genomically integrated expression cassette, wherein the expression cassette comprises:

(a) a nucleic acid encoding a chimeric Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to a transcriptional activation domain; and

(b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor fused to transcriptional activation domains,

wherein the expression cassette further comprises a polyadenylation signal or transcription terminator upstream of the nucleic acid encoding the chimeric Cas protein,

wherein the polyadenylation signal or transcription terminator is flanked by recombinase recognition sites recognized by a site-specific recombinase,

wherein the expression cassette comprises the sequence set forth in SEQ ID NO: 31.

2 . The non-human animal of claim 1 , wherein the polyadenylation signal or transcription terminator has been excised in a tissue in the non-human animal.

3 . The non-human animal of claim 2 , further comprising one or more guide RNAs or an expression cassette encoding one or more guide RNAs, wherein the one or more guide RNAs each comprise one or more adaptor-binding elements to which the chimeric adaptor protein can specifically bind, and wherein the one or more guide RNAs form complexes with the chimeric Cas protein and chimeric adaptor protein and guide them to a target sequence within a target gene, increasing expression of the target gene.

4 . The non-human animal of claim 3 , wherein the target gene is a gene expressed in the liver.

5 . The non-human animal of claim 3 , wherein the target sequence comprises a regulatory sequence within the target gene, and wherein the regulatory sequence comprises a promoter or an enhancer.

6 . The non-human animal of claim 3 , wherein the target sequence is within 200 base pairs of the transcription start site of the target gene, or wherein the target sequence is within the region 200 base pairs upstream of the transcription start site and 1 base pair downstream of the transcription start site.

7 . The non-human animal of claim 3 , wherein each of the one or guide RNAs comprises two adaptor-binding elements to which the chimeric adaptor protein can specifically bind, and wherein a first adaptor-binding element is within a first loop of each of the one or more guide RNAs, and a second adaptor-binding element is within a second loop of each of the one or more guide RNAs.

8 . The non-human animal of claim 7 , wherein each of one or more guide RNAs is a single guide RNA comprising a CRISPR RNA (crRNA) portion fused to a transactivating CRISPR RNA (tracrRNA) portion, and

wherein the first loop is the tetraloop corresponding to residues 13-16 of SEQ ID NO: 12 and the second loop is the stem loop 2 corresponding to residues 53-56 of SEQ ID NO: 12.

9 . The non-human animal of claim 3 , wherein the adaptor-binding element comprises the sequence set forth in SEQ ID NO: 16, or wherein each of the one or more guide RNAs comprises the sequence set forth in SEQ ID NO: 40 or 63.

10 . The non-human animal of claim 3 , wherein at least one of the one or more guide RNAs targets a disease-associated gene.

11 . The non-human animal of claim 10 , wherein the disease-associated gene is a Ttr gene, and wherein the Ttr-targeting guide RNA targets a sequence comprising the sequence set forth in any one of SEQ ID NOS: 34-36 or wherein the Ttr-targeting guide RNA comprises the sequence set forth in any one of SEQ ID NOS: 37-39.

12 . The non-human animal of claim 3 , wherein at least one of the one or more guide RNAs targets a Pcsk9 gene, and wherein the Pcsk9-targeting guide RNA targets a sequence comprising the sequence set forth in any one of SEQ ID NOS: 89-91 or wherein the Pcsk9-targeting guide RNA comprises the sequence set forth in any one of SEQ ID NOS: 92-94, and wherein the method causes hypercholesterolemia in the non-human animal.

13 . The non-human animal of claim 3 , wherein at least one of the one or more guide RNAs targets a Ldlr gene, and wherein the Ldlr-targeting guide RNA targets a sequence comprising the sequence set forth in any one of SEQ ID NOS: 75-77 or wherein the Ldlr-targeting guide RNA comprises the sequence set forth in any one of SEQ ID NOS: 78-80.

14 . The non-human animal of claim 3 , wherein the one or more guide RNAs target two or more target genes, or wherein the one or more guide RNAs comprise multiple guide RNAs that target a single target gene.

15 . The non-human animal of claim 14 , wherein the one or more guide RNAs comprise at least three guide RNAs that target a single target gene.

16 . The non-human animal of claim 15 , wherein:

(a) the at least three guide RNAs target the mouse Ttr locus, and wherein a first guide RNA targets a sequence comprising SEQ ID NO: 34 or comprises the sequence set forth in SEQ ID NO: 37, a second guide RNA targets a sequence comprising SEQ ID NO: 35 or comprises the sequence set forth in SEQ ID NO: 38, and a third guide RNA targets a sequence comprising SEQ ID NO: 36 or comprises the sequence set forth in SEQ ID NO: 39;

(b) the at least three guide RNAs target the mouse Pcsk9 locus, and wherein a first guide RNA targets a sequence comprising SEQ ID NO: 89 or comprises the sequence set forth in SEQ ID NO: 92, a second guide RNA targets a sequence comprising SEQ ID NO: 90 or comprises the sequence set forth in SEQ ID NO: 93, and a third guide RNA targets a sequence comprising SEQ ID NO: 91 or comprises the sequence set forth in SEQ ID NO: 94; or

(c) the at least three guide RNAs target the mouse Ldlr locus, and wherein a first guide RNA targets a sequence comprising SEQ ID NO: 75 or comprises the sequence set forth in SEQ ID NO: 78, a second guide RNA targets a sequence comprising SEQ ID NO: 76 or comprises the sequence set forth in SEQ ID NO: 79, and a third guide RNA targets a sequence comprising SEQ ID NO: 77 or comprises the sequence set forth in SEQ ID NO: 80.

17 . The non-human animal of claim 3 , wherein the non-human animal comprises the one or more guide RNAs in the form of RNA.

18 . The non-human animal of claim 3 , wherein the non-human animal comprises the expression cassette encoding the one or more guide RNAs.

19 . The non-human animal of claim 18 , wherein the expression cassette encoding the one or more guide RNAs is genomically integrated.

20 . The non-human animal of claim 18 , wherein each of the one or more guide RNAs is encoded by a DNA operably linked to a separate U6 promoter.

21 . The non-human animal of claim 18 , wherein the expression cassette encoding the one or more guide RNAs is genomically integrated, wherein each of the one or more guide RNAs is encoded by a DNA operably linked to a separate U6 promoter, and wherein the one or more guide RNAs comprise multiple guide RNAs that target a single target gene.

22 . The non-human animal of claim 1 , wherein the non-human animal further comprises a Cre recombinase expression cassette comprising a Cre recombinase coding sequence operably linked to a tissue-specific promoter, and the polyadenylation signal or transcription terminator has been excised in a tissue-specific manner, or wherein the non-human animal further comprises a Cre recombinase.

23 . The non-human animal of claim 22 , wherein the non-human animal comprises a genomically integrated Cre recombinase expression cassette comprising the Cre recombinase coding sequence operably linked to the tissue-specific promoter, wherein the tissue-specific promoter is an albumin promoter.

24 . The non-human animal of claim 1 , wherein the genomically integrated expression cassette is integrated into a safe harbor locus, and wherein the expression cassette is operably linked to an endogenous promoter in the safe harbor locus.

25 . The non-human animal of claim 24 , wherein the safe harbor locus is a Rosa26 locus.

26 . The non-human animal of claim 1 , wherein the non-human animal is a mammal.

27 . The non-human animal of claim 26 , wherein the mammal is a rodent that is a rat or a mouse.

28 . The non-human animal of claim 27 , wherein the rodent is the mouse.

29 . A non-human animal cell of the non-human animal of claim 1 , wherein the non-human animal cell comprises a genomically integrated expression cassette, wherein the expression cassette comprises:

(a) a nucleic acid encoding a chimeric Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated (Cas) protein comprising a nuclease-inactive Cas protein fused to a transcriptional activation domain; and

(b) a nucleic acid encoding a chimeric adaptor protein comprising an adaptor fused to transcriptional activation domains,

wherein the expression cassette further comprises a polyadenylation signal or transcription terminator upstream of the nucleic acid encoding the chimeric Cas protein,

wherein the polyadenylation signal or transcription terminator is flanked by recombinase recognition sites recognized by a site-specific recombinase,

wherein the expression cassette comprises the sequence set forth in SEQ ID NO: 31.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2025
From: HUNT, CHARLEEN; HARTFORD, SUZANNE; GONG, GUOCHUN; ZAMBROWICZ, BRIAN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 070530/0822 →
Continuity (3)
Division 16358395 · Mar 19, 2019
Provisional Application 62644961 · Mar 19, 2018
Related Publication 20230123296A1 · Apr 20, 2023
References Cited (196)
US 5942435A · Wheeler · 1999 [cited by applicant]
US 6586251B2 · Economides et al. · 2003 [cited by applicant]
US 7294754B2 · Poueymirou et al. · 2007 [cited by applicant]
US 7576259B2 · Poueymirou et al. · 2009 [cited by applicant]
US 7659442B2 · Poueymirou et al. · 2010 [cited by applicant]
US 10329582B2 · Lee et al. · 2019 [cited by applicant]
US 10385359B2 · Lee et al. · 2019 [cited by applicant]
US 10550372B2 · Konermann et al. · 2020 [cited by applicant]
US 10577630B2 · Zhang et al. · 2020 [cited by applicant]
US 10760064B2 · Joung et al. · 2020 [cited by applicant]
US 11001829B2 · Zhang et al. · 2021 [cited by applicant]
US 11519004B2 · Hunt et al. · 2022 [cited by applicant]
US 11597919B2 · Konermann et al. · 2023 [cited by applicant]
US 20080078000A1 · Poueymirou et al. · 2008 [cited by applicant]
US 20140178879A1 · Economides et al. · 2014 [cited by applicant]
US 20140235933A1 · Lee et al. · 2014 [cited by applicant]
US 20140310828A1 · Lee et al. · 2014 [cited by applicant]
US 20150071899A1 · Liu et al. · 2015 [cited by applicant]
US 20150376628A1 · Schoenherr et al. · 2015 [cited by applicant]
US 20150376651A1 · Frendewey et al. · 2015 [cited by applicant]
US 20160058889A1 · Olson et al. · 2016 [cited by applicant]
US 20160145646A1 · Frendewey et al. · 2016 [cited by applicant]
US 20160151491A1 · Rabinovich et al. · 2016 [cited by applicant]
US 20160208288A1 · Liu et al. · 2016 [cited by applicant]
US 20160222416A1 · Church et al. · 2016 [cited by applicant]
US 20160237456A1 · Church et al. · 2016 [cited by applicant]
US 20160243260A1 · Blits · 2016 [cited by applicant]
US 20160257974A1 · Bradley et al. · 2016 [cited by applicant]
US 20160281072A1 · Zhang · 2016 [cited by applicant]
US 20160326548A1 · Cost · 2016 [cited by applicant]
US 20160355797A1 · Konermann et al. · 2016 [cited by applicant]
US 20170107536A1 · Zhang et al. · 2017 [cited by applicant]
US 20170204407A1 · Gilbert et al. · 2017 [cited by applicant]
US 20170239370A1 · Zhu et al. · 2017 [cited by applicant]
US 20180057810A1 · Zhang et al. · 2018 [cited by applicant]
US 20180110877A1 · Wilson et al. · 2018 [cited by applicant]
US 20180119122A1 · Zhang et al. · 2018 [cited by applicant]
US 20180179553A1 · Watson et al. · 2018 [cited by applicant]
US 20180185516A1 · Ansell et al. · 2018 [cited by applicant]
US 20190002869A1 · Yin et al. · 2019 [cited by applicant]
US 20190032053A1 · Ji et al. · 2019 [cited by applicant]
US 20190038780A1 · Largaespada et al. · 2019 [cited by applicant]
US 20190106693A1 · Rinn et al. · 2019 [cited by applicant]
US 20190233814A1 · Zhang et al. · 2019 [cited by applicant]
US 20190284572A1 · Hunt et al. · 2019 [cited by applicant]
US 20190365924A1 · Conway et al. · 2019 [cited by applicant]
US 20190376060A1 · Vora et al. · 2019 [cited by applicant]
US 20190376090A1 · Joung et al. · 2019 [cited by applicant]
US 20190390195A1 · Tondera et al. · 2019 [cited by applicant]
US 20200115687A1 · Konermann et al. · 2020 [cited by applicant]
US 20200248168A1 · Lundberg et al. · 2020 [cited by applicant]
US 20200392541A1 · Zhang et al. · 2020 [cited by applicant]
US 20210079394A1 · Hunt et al. · 2021 [cited by applicant]
US 20210102206A1 · Liao et al. · 2021 [cited by applicant]
US 20210269831A1 · Zhang et al. · 2021 [cited by applicant]
US 20240002839A1 · Drummond Samuelson et al. · 2024 [cited by applicant]
US 20240035007A1 · Konermann et al. · 2024 [cited by applicant]
EP 3045537A1 · 2016 [cited by applicant]
EP 30644585A1 · 2016 [cited by applicant]
EP 2877571B1 · 2018 [cited by applicant]
EP 3392337A1 · 2018 [cited by applicant]
EP 3620524A1 · 2018 [cited by applicant]
EP 3003392B1 · 2019 [cited by applicant]
EP 3080271B1 · 2020 [cited by applicant]
WO WO2001005962A2 · 2001 [cited by applicant]
WO WO2013071440A1 · 2013 [cited by applicant]
WO WO2014093622A2 · 2014 [cited by applicant]
WO WO2014093655A2 · 2014 [cited by applicant]
WO WO2014093701A1 · 2014 [cited by applicant]
WO WO2014130706A1 · 2014 [cited by applicant]
WO WO2014172489A2 · 2014 [cited by applicant]
WO WO2014197568A2 · 2014 [cited by applicant]
WO WO2015006294A2 · 2015 [cited by applicant]
WO WO2015035139A2 · 2015 [cited by applicant]
WO WO2015040075A1 · 2015 [cited by applicant]
WO WO2015042557A1 · 2015 [cited by applicant]
WO WO2015088643A1 · 2015 [cited by applicant]
WO WO2015089486A2 · 2015 [cited by applicant]
WO WO2015200334A1 · 2015 [cited by applicant]
WO WO2015200805A2 · 2015 [cited by applicant]
WO WO2016044745A1 · 2016 [cited by applicant]
WO WO2016049258A2 · 2016 [cited by applicant]
WO WO2016081923A2 · 2016 [cited by applicant]
WO WO2016094872A1 · 2016 [cited by applicant]
WO WO2016094874A1 · 2016 [cited by applicant]
WO WO2016137949A1 · 2016 [cited by applicant]
WO WO2016149484A2 · 2016 [cited by applicant]
WO WO2016176191A1 · 2016 [cited by applicant]
WO WO2017011721A1 · 2017 [cited by applicant]
WO WO2017087780A1 · 2017 [cited by applicant]
WO WO2017106657A1 · 2017 [cited by applicant]
WO WO2017173054A1 · 2017 [cited by applicant]
WO WO2017180915A2 · 2017 [cited by applicant]
WO WO2018007871A1 · 2018 [cited by applicant]
WO WO2018009869A1 · 2018 [cited by applicant]
WO WO2018085644A1 · 2018 [cited by applicant]
WO WO2018096343A1 · 2018 [cited by applicant]
WO WO2018107026A1 · 2018 [cited by applicant]
WO WO2018107028A1 · 2018 [cited by applicant]
WO WO2018119354A1 · 2018 [cited by applicant]
WO WO2018154380A1 · 2018 [cited by applicant]
WO WO2019027728A1 · 2019 [cited by applicant]
WO WO2019183123A1 · 2019 [cited by applicant]
WO WO2019236081A1 · 2019 [cited by applicant]
WO WO2019237069A1 · 2019 [cited by applicant]
WO WO2019246203A1 · 2019 [cited by applicant]
WO WO2020142714A1 · 2020 [cited by applicant]
WO WO2021108363A1 · 2021 [cited by applicant]
Hunt et al., “Tissue-specific activation of gene expression by the Synergistic Activation Mediator (SAM) CRISPRa system in mice,” Nat. Commun., 12(1):2770, (May 13, 2021). [cited by applicant]
Omer, et al., “CRISPR Correction of a Homozygous Low-Density Lipoprotein Receptor Mutation in Familial Hypercholesterolemia Induced Pluripotent Stem Cells,” Hepatol. Commun., 1(9):886-898, (Oct. 16, 2017). [cited by applicant]
Yin, et al., “Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing,” Nat. Biotechnol., 35(12):1179-1187, (Nov. 13, 2017). [cited by applicant]
Addgene Product Catalogue, plasmid #61425, pp. 10-13, retrieved at www.addgene.org/61425/ on Apr. 26, 2022, (2022). [cited by applicant]
Baeumler, et al., “Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors,” Cell Rep., 20(11):2639-2653, (2017). [cited by applicant]
Barthold, “Genetically altered mice: phenotypes, no phenotypes, and Faux phenotypes,” Genetica, 122(1):75-88, (2004). [cited by applicant]
Birling, et al., “Modeling human disease in rodents by CRISPR/Cas9 genome editing,” Mamm. Genome, 28(7-8):291-301, (2017). [cited by applicant]
Brevini, et al., “No shortcuts to pig embryonic stem cells,” Theriogenology, 74(4):544-550, (2010). [cited by applicant]
Brevini, et al., “Porcine embryonic stem cells: Facts, challenges and hopes,” Theriogenology, 68 Suppl. 1:S206-S213, (2007). [cited by applicant]
Burova, et al., “Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice,” Mol. Cancer Ther., 16(5):861-870, (2017). [cited by applicant]
Cao, et al., “Isolation and Culture of Primary Bovine Embryonic Stem Cell Colonies by a Novel Method,” J. Exp. Zool. A. Ecol. Genet. Physiol., 311(5):368-376, (2009). [cited by applicant]
Cas9 SAM, “Cas9-Activators with SAM” [Retrieved from the Internet Oct. 19, 2017 <http://sam.genone-engineering.org/>]. [cited by applicant]
Chavez, et al., “Comparison of Cas9 activators in multiple species,” Nat. Methods, 13(7):563-567, (2016). [cited by applicant]
Chow et al., “AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma,” Nat. Neurosci. 20(10):1329-1341 plus supplementary materials, (Aug. 14, 2017). [cited by applicant]
Clark, et al., “A future for transgenic livestock,” Nat. Rev. Genet., 4(10):825-833, (2003). [cited by applicant]
Dahlman, et al., “Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease,” Nat. Biotechnol., 33(11):1159-1161, (2015). [cited by applicant]
Dechiara, T.M., et al., “VelociMouse: Fully ES Cell-Derived FO-Generation Mice Obtained from the Injection of ES Cells into Eight-Cell-Stage Embryos,” Jan. 1, 2009, Methods in Molecular Biology, 530(16): 311-324. [cited by applicant]
Dennis, “Welfare Issues of Genetically Modified Animals,” ILAR J., 43(2):100-109, (2002). [cited by applicant]
Dominguez, et al., “Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation,” Nat. Rev. Mol. Cell. Biol., 17(1):5-15, (2016). [cited by applicant]
Evers, et al., “CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes,” Nature Biotechnology, 34(6):631-633 plus Online Methods, (Jun. 2016). [cited by applicant]
Finn, et al., “A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing,” Cell Reports, 22:1-9, (Feb. 27, 2018). [cited by applicant]
Frendewey, et al., “The Loss-of-Allele Assay for ES Cell Screening and Mouse Genotyping,” Methods Enzymol., 476:295-307, (2010). [cited by applicant]
Friedrich, et al., “Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice,” Genes Dev., 5(9):1513-1523, (1991). [cited by applicant]
Genoway, “Humanized Mouse Model,” retrieved from https://www.genoway.com/services/customized-mouse/knockin-models/humanisation.htm on May 12, 2018. [cited by applicant]
Gertz, et al., “Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis,” J. Am. Coll. Cardiol., 66(21):2451-2466, (2015). [cited by applicant]
Gomez, et al., “Derivation of cat embryonic stem-like cells from in vitro-produced blastocysts on homologous and heterologous feeder cells,” Theriogenology, 74(4): 498-515, (2010). [cited by applicant]
Graham, et al., “Resources for the design of CRISPR gene editing experiments,” Genome Biol., 16:260, (2015). [cited by applicant]
Haapaniemi et al., “CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response,” Nat. Med. doi: 10.1038/s41591-018-0049-z, (Jun. 11, 2018, epub ahead of print). [cited by applicant]
Harari, et al., “Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response,” PLoS ONE, 9(1): e84259, (2014). [cited by applicant]
Herndler-Brandstetter, et al., “Humanized mouse model supports development, function, and tissue residency of human natural killer cells,” Proc. Natl. Acad. Sci. U.S.A., 114(45):E9626-E9634, (2017). [cited by applicant]
Hopkins, et al., “Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody,” Circ. Cardiovasc. Genet.… [cited by applicant]
Houdebine, “Methods to Generate Transgenic Animals,” pp. 31-48 in “Genetic Engineering in Livestock: New Applications and Interdisciplinary Perspectives,” Ed. Engelhard et al., (2009). [cited by applicant]
Ihry et al., “p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells,” Nat. Med. doi: 10.1038/s41591-018-0050-6 (Jun. 11, 2018, epub ahead of print). [cited by applicant]
Jean, et al., “Pluripotent genes in avian stem cells,” Dev. Growth Differ., 55(1): 41-51, (2013). [cited by applicant]
Jensen, “Design principles for nuclease-deficient CRISPR-based transcriptional regulators,” FEMS Yeast Res., 18(4), doi:10.1093/femsyr/foy039, (2018). [cited by applicant]
Jia, et al., “Next-generation CRISPR/Cas9 transcriptional activation in [cited by applicant]
Joung, et al., “Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening,” Nature Protocols, 12(4):828-863, (2017). [cited by applicant]
Kawamata, et al., “Generation of genetically modified rats from embryonic stem cells,” Proc. Natl. Acad. Sci. U.S.A., 7(32):14223-14228, (2010). [cited by applicant]
Konermann, et al., “Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex,” Nature, 517:583-588 plus Extended Data, (Jan. 29, 2017). [cited by applicant]
Kosicki et al., “Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements,” Nat. Biotechnol., 36(8): 765-771, (Jul. 16, 2018). [cited by applicant]
Kumar, et al., “Transgenic Mouse Technology: Principles and Methods,” Methods Mol. Biol., 590:335-362, (2009). [cited by applicant]
La Russa, et al., “The New State of the Art: Cas9 for Gene Activation and Repression,” Mol. Cell. Biol., 35(22):3800-3809, (2015). [cited by applicant]
Lau, et al., “Targeted Transgene Activation in the Brain Tissue by Systemic Delivery of Engineered AAV1 Expressing CRISPRa,” Mol. Ther. Nucleic Acids, 16:637-649, (2019). [cited by applicant]
Lau, et al., “In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease,” F1000Res, 6:2153, doi:10.12688/f1000research. 11243.1, (2017). [cited by applicant]
Liao, et al., “Amyloid Cardiomyopathy, Disease on the Rise,” Circ. Res., 120(12):1865-1867, (2017). [cited by applicant]
Liao, et al., “In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation,” Cell, 171(7):1495-1507.e15 (2017). [cited by applicant]
Liu, et al., “Editing DNA Methylation in the Mammalian Genome,” Cell, 167(1):233-247.e17 (2016). [cited by applicant]
Liu, et al., “Specific Expression of Interferon-gamma Induced by Synergistic Activation Mediator-Derived Systems Activates Innate Immunity and Inhibits Tumorigenesis,” J. Microbiol. Biotechnol., 27(10):1855-1866, (2017). [cited by applicant]
Lundh, et al., “Bidirectional manipulation of gene expression in adipocytes using CRISPRa and siRNA,” Mol. Metab., 6(10):1313-1320, (2017). [cited by applicant]
Lute, et al., “Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies,” Blood, 106(9):3127-3133, (2005). [cited by applicant]
Malina et al., “Repurposing CRISPR/Cas9 for in situ functional assays,” Genes Dev., vol. 27(23):2602-2614, (2013). [cited by applicant]
Matharu, et al., “CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency,” Science, 363(6424), doi:10.1126/science.aau0629, (2019). [cited by applicant]
Morgens, et al., “Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes,” Nature Biotechnology, 34(6):634-636 plus Online Methods, (Jun. 2016). [cited by applicant]
Mullins, et al., “Transgenesis in the rat and larger mammals,” J. Clin. Invest. 97(7):1557-1560, (1996). [cited by applicant]
Munoz, et al., “Conventional pluripotency markers are unspecific forderived cell-lines,” Theriogenology, 69(9): 1159-1164, (2008). [cited by applicant]
Niemann, “Transgenic farm animals get off the ground. Transgenic Animals in Agriculture, Conference Tahoe City, California, USA. Aug. 24-27, 1997.” Transgenic Res., 7(1): 73-75, (1998). [cited by applicant]
Nishimasu, et al., “Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA,” Cell, 156:935-949, (Feb. 27, 2014). [cited by applicant]
Paris, et al., “Equine embryos and embryonic stem cells: defining reliable markers of pluripotency,” Theriogenology, 74(4): 516-524, (2010). [cited by applicant]
Platt, et al., “CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling,” Cell, 159:440-455, (Oct. 9, 2014). [cited by applicant]
Poueymirou, et al., “F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses,” Nat. Biotechnol., 25(1):91-99, (2007). [cited by applicant]
Ran et al., “In vivo genome editing using [cited by applicant]
Rezza, et al., “Unexpected genomic rearrangements at targeted loci associated with CRISPR/Cas9-mediated knock-in,” Sci. Rep., 9(1):3486, (2019). [cited by applicant]
Ristevski, “Making better transgenic models: conditional, temporal, and spatial approaches,” Mol. Biotechnol., 29(2):153-163, (2005). [cited by applicant]
Rogers, et al., “Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs,” Science, 321(5897):1837-1841, (2008). [cited by applicant]
Senis, et al., “CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox,” Biotechnol. J., 9(11):1402-1412, (2014). [cited by applicant]
Shalem, et al., “Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells,” Science, 343:84-87, (Jan. 3, 2014). [cited by applicant]
Shalem, et al., “High-throughput functional genomics using CRISPR-Cas9,” Nature Reviews: Genetics, 16:299-311, (May 2015). [cited by applicant]
Shapiro, et al., “PCSK9: From Basic Science Discoveries to Clinical Trials,” Circ. Res., 122(10):1420-1438, (2018). [cited by applicant]
Sigmund, “Viewpoint: Are Studies in Genetically Altered Mice out of Control?,” Arterioscler. Thromb. Vasc. Biol., 20(6):1425-1429, (2000). [cited by applicant]
Ueda, et al., “Recent advances in transthyretin amyloidosis therapy,”3:19, doi: 10.1186/2047-9158-3-19, (2014). [cited by applicant]
Valenzuela, et al., “High-throughput engineering of the mouse genome coupled with high-resolution expression analysis,” Nat. Biotechnol., 21(6):652-659, (2003). [cited by applicant]
Vora, et al., “Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery,” bioRxiv, doi: 10.1101/298620, (2018). [cited by applicant]
Wakchaure, et al., “Transgenic Animals: A Review on its Various Dimensions and Applications in Animal Biotechnology,” International Journal of Emerging Technology and Advanced Engineering, 5(11):210-213, (2015). [cited by applicant]
Wang et al., “Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening,” Sci. Adv. 4(2):eaao5508, (Feb. 28, 2018). [cited by applicant]
Wangensteen, al et., “Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform,” Hepatology, 68(2):663-676, (2018). [cited by applicant]
Xu, et al., “CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo,” Oncotarget, 8(60):102078-102087, (2017). [cited by applicant]
Yin, et al., “Delivery technologies for genome editing,” Nat. Rev. Drug Discov., 16(6):387-399, (2017). [cited by applicant]
Zambrowicz, et al., “Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells,” Proc. Natl. Acad. Sci. … [cited by applicant]
Zhang Lab—CRISPR Mouse Activation Pooled Library (SAM v1) [Retrieved from the Internet Oct. 19, 2017 <https://www.addgene.org/pooled-library/zhang-mouse-sam-v1/>]. [cited by applicant]
Zhang, et al., “CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs,” Scientific Reports, 5:16277, (Nov. 5, 2015). [cited by applicant]
Zhao, et al., “Inconsistency between hepatic expression and serum concentration of transthyretin in mice humanized at the transthyretin locus,” Genes to Cells, 13:1257-1268, (2008). [cited by applicant]
Zhou, et al., “Developing tTA transgenic rats for inducible and reversible gene expression,” Int. J. Biol. Sci., 5(2):171-181, (2009). [cited by applicant]
Zhou, et al., “In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice,” Nat. Neurosci., 21(3):440-446, (Jan. 15, 2018). [cited by applicant]
U.S. Appl. No. 16/358,395, Final Office Action mailed May 2, 2022. [cited by applicant]
U.S. Appl. No. 16/358,395, Non-Final Office Action mailed Oct. 22, 2021. [cited by applicant]
U.S. Appl. No. 16/358,395, Notice of Allowance and Interview Summary mailed Aug. 2, 2022. [cited by applicant]
U.S. Appl. No. 16/358,395, Requirement for Restriction/Election mailed Jun. 11, 2021. [cited by applicant]
WIPO Application No. PCT/US2019/023009, PCT International Search Report and Written Opinion of the International Searching Authority mailed May 21, 2019. [cited by applicant]